Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137


Hepatitis C transmission and treatment in contact networks of people who inject drugs.

Rolls DA, Sacks-Davis R, Jenkinson R, McBryde E, Pattison P, Robins G, Hellard M.

PLoS One. 2013 Nov 1;8(11):e78286. doi: 10.1371/journal.pone.0078286. eCollection 2013.


Hepatitis C transmission and treatment as prevention - The role of the injecting network.

Hellard M, McBryde E, Sacks Davis R, Rolls DA, Higgs P, Aitken C, Thompson A, Doyle J, Pattison P, Robins G.

Int J Drug Policy. 2015 Oct;26(10):958-62. doi: 10.1016/j.drugpo.2015.05.006. Epub 2015 May 21.


Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia.

Hellard ME, Jenkinson R, Higgs P, Stoové MA, Sacks-Davis R, Gold J, Hickman M, Vickerman P, Martin NK.

Med J Aust. 2012 Jun 4;196(10):638-41.


The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals?

Stone J, Martin NK, Hickman M, Hellard M, Scott N, McBryde E, Drummer H, Vickerman P.

PLoS One. 2016 May 25;11(5):e0156213. doi: 10.1371/journal.pone.0156213. eCollection 2016.


Modeling hepatitis C virus transmission among people who inject drugs: Assumptions, limitations and future challenges.

Scott N, Hellard M, McBryde ES.

Virulence. 2016;7(2):201-8. doi: 10.1080/21505594.2015.1085151. Epub 2015 Aug 25. Review.


The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments.

Scott N, McBryde E, Vickerman P, Martin NK, Stone J, Drummer H, Hellard M.

BMC Med. 2015 Aug 20;13:198. doi: 10.1186/s12916-015-0440-2.


Assessing the Long-Term Impact of Treating Hepatitis C Virus (HCV)-Infected People Who Inject Drugs in the UK and the Relationship between Treatment Uptake and Efficacy on Future Infections.

Bennett H, McEwan P, Sugrue D, Kalsekar A, Yuan Y.

PLoS One. 2015 May 4;10(5):e0125846. doi: 10.1371/journal.pone.0125846. eCollection 2015.


Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia.

Scott N, Iser DM, Thompson AJ, Doyle JS, Hellard ME.

J Gastroenterol Hepatol. 2016 Apr;31(4):872-82. doi: 10.1111/jgh.13223.


HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact.

Martin NK, Foster GR, Vilar J, Ryder S, Cramp ME, Gordon F, Dillon JF, Craine N, Busse H, Clements A, Hutchinson SJ, Ustianowski A, Ramsay M, Goldberg DJ, Irving W, Hope V, De Angelis D, Lyons M, Vickerman P, Hickman M.

J Viral Hepat. 2015 Apr;22(4):399-408. doi: 10.1111/jvh.12338. Epub 2014 Oct 7.


Mathematical Modeling of Hepatitis C Prevalence Reduction with Antiviral Treatment Scale-Up in Persons Who Inject Drugs in Metropolitan Chicago.

Echevarria D, Gutfraind A, Boodram B, Major M, Del Valle S, Cotler SJ, Dahari H.

PLoS One. 2015 Aug 21;10(8):e0135901. doi: 10.1371/journal.pone.0135901. eCollection 2015.


Eligibility of persons who inject drugs for treatment of hepatitis C virus infection.

Arain A, Robaeys G.

World J Gastroenterol. 2014 Sep 28;20(36):12722-33. doi: 10.3748/wjg.v20.i36.12722. Review.


Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs?

Lima VD, Rozada I, Grebely J, Hull M, Lourenco L, Nosyk B, Krajden M, Yoshida E, Wood E, Montaner JS.

PLoS One. 2015 Dec 3;10(12):e0143836. doi: 10.1371/journal.pone.0143836. eCollection 2015.


Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence.

Hickman M, De Angelis D, Vickerman P, Hutchinson S, Martin NK.

Curr Opin Infect Dis. 2015 Dec;28(6):576-82. doi: 10.1097/QCO.0000000000000216. Review.


The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs.

Hellard M, Rolls DA, Sacks-Davis R, Robins G, Pattison P, Higgs P, Aitken C, McBryde E.

Hepatology. 2014 Dec;60(6):1861-70. doi: 10.1002/hep.27403. Epub 2014 Oct 24.


Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care.

Zeremski M, Zibbell JE, Martinez AD, Kritz S, Smith BD, Talal AH.

World J Gastroenterol. 2013 Nov 28;19(44):7846-51. doi: 10.3748/wjg.v19.i44.7846. Review.


Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C.

Alavi M, Spelman T, Matthews GV, Haber PS, Day C, van Beek I, Walsh N, Yeung B, Bruneau J, Petoumenos K, Dolan K, Kaldor JM, Dore GJ, Hellard M, Grebely J; ATAHC Study Group.

Int J Drug Policy. 2015 Oct;26(10):976-83. doi: 10.1016/j.drugpo.2015.05.003. Epub 2015 May 21.


Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes.

Ruta S, Cernescu C.

World J Gastroenterol. 2015 Oct 14;21(38):10811-23. doi: 10.3748/wjg.v21.i38.10811. Review.


Exploratory social network analysis and gene sequencing in people who inject drugs infected with hepatitis C virus.

Wang Y, Tan XD, Zhou C, Zhou W, Peng JS, Ren YS, Ni ZL, Liu B, Yang F, Gao XD.

Epidemiol Infect. 2016 Oct;144(14):3080-3090. Epub 2016 Jul 13.


Mitigating the burden of hepatitis C virus among people who inject drugs in Belgium.

Matheï C, Bourgeois S, Blach S, Brixko C, Mulkay JP, Razavi H, Robaeys G.

Acta Gastroenterol Belg. 2016 Apr-Jun;79(2):227-32.


Hepatitis C virus vaccines among people who inject drugs.

Cox AL, Thomas DL.

Clin Infect Dis. 2013 Aug;57 Suppl 2:S46-50. doi: 10.1093/cid/cit329. Review.

Supplemental Content

Support Center